Truist Financial’s TG Therapeutics TGTX Stock Holding History

Truist Financial’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.33M	Buy	24,226 +1,950	+9%	+$79.8K	﹤0.01%	1607
2026 Q1	$740K	Buy	+22,276	New	+$664K	﹤0.01%	1862
2021 Q1	–	Sell	-4,366	Closed	-$227K	–	2725
2020 Q4	$227K	Buy	+4,366	New	+$148K	﹤0.01%	2323
2020 Q2	–	Sell	-12,700	Closed	-$125K	–	2578
2020 Q1	$125K	Buy	+12,700	New	+$160K	﹤0.01%	2224

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Truist Financial's TGTX Position: Q2 2026 in Review

Truist Financial increased its TG Therapeutics (TGTX) stake by 8.8% in Q2 2026, buying an estimated $79.8K and bringing the position to 24,226 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1607.

Truist Financial first reported a position in TGTX in Q1 2020 and has held it in 4 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Truist Financial held 24,226 shares of TG Therapeutics worth $1.33M as of Q2 2026.
Truist Financial bought 1,950 TG Therapeutics shares in Q2 2026, an estimated $79.8K.
TG Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #1607 holding.
Truist Financial first reported a position in TG Therapeutics in Q1 2020 and has held it in 4 quarters since.
430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.